Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aditxt Inc (NQ: ADTX )

0.3572 +0.0052 (+1.48%)
Streaming Delayed Price Updated: 10:45 AM EST, Dec 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aditxt Inc

< Previous 1 2 3 4 5 6 7 8 Next >
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Reaches Pivotal Milestone to Advance ADI (TM) Technology
Via Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Dedicated to New Era of Precision Medicine
Via Investor Brand Network
Aditxt, Inc. (NASDAQ: ADTX) Bolsters Goal to Conduct First-In-Human Clinical Trial Evaluating ADI(TM) Tech with Formation of Adimune, Inc. Subsidiary; Appoints Industry Veteran as Subsidiary Chairman and CEO
Via Investor Brand Network
Research Explains Why MS Patients Benefit from Stem Cell Transplants
Via Investor Brand Network
Why Food Allergies May Be Increasing
Via Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms Subsidiary with Focus on Immune Modulation Therapies
Via Investor Brand Network
Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO
From Aditxt, Inc.
Via Business Wire
Aditxt Inc. (NASDAQ: ADTX) Announces Goal of First-in-Human Trials for Drug Candidate ADI(TM)-100 with a Focus on Psoriasis
Via Investor Brand Network
Researchers Look to AI to Improve Organ Transplant Processes
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Equity Research Reports
Via Investor Brand Network
Exposures COVID-19
Department of Defense Awards Scientists at University of Buffalo $4M Grant to Study Concussion Treatment
Via Investor Brand Network
Genes That Saved People from Bubonic Plague Linked to Autoimmune Conditions Today
Via Investor Brand Network
Research Finds That Stem Cells Reduce Lung Transplant Rejection Rates
Via Investor Brand Network
Study Finds Livers with a Cumulative Age of 100 Years
Via Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Key Milestone in Advancing Adimune(TM) Program
Via Investor Brand Network
Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis First-in-Human Trials
From Aditxt, Inc.
Via Business Wire
Allergies: How They Occur and Why They Sometimes Disappear
Via Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Publication of Innovative Mathematical Model
Via Investor Brand Network
Exposures COVID-19
Aditxt, Inc. (Nasdaq: ADTX) Announces Development and Publication of a Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection
From Aditxt, Inc.
Via Business Wire
BioMedNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Featured in FedEx Video Presentation
Via Investor Brand Network
Exposures COVID-19
People with Autoimmune Disorders More Likely to Suffer Post-Heart Attack Complications, Study Finds
Via Investor Brand Network
FedEx Features AditxtScore™ Immune Monitoring Center and its Service in Richmond, VA, Highlighting the Importance of Quantifying Immune Health
From Aditxt, Inc.
Via Business Wire
Transplant Team at UW Medicine Completes Groundbreaking Surgery
Via Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements
Via Investor Brand Network
Aditxt, Inc. (NASDAQ: ADTX) Announces That it Has Regained Compliance with Nasdaq Listing Requirements
From Aditxt, Inc.
Via Business Wire
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Issues Corporate Update Following Reverse Stock Split, Closing of $20M Public Offering
Via Investor Brand Network
Aditxt Inc. (Nasdaq: ADTX) Provides Corporate Highlights Post Reverse Stock Split and Closing of $20M Public Offering
From Aditxt, Inc.
Via Business Wire
UBC Scientists Believe Insulin Tablet to Treat Diabetes May Soon Be Available
Via Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Closes on Recently Announced $20M Public Offering
Via Investor Brand Network
Aditxt Announces Closing of $20.0 Million Public Offering
From Aditxt, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.